NASDAQ: $ACRS
New Hope for Lichen Planus Patients
There is promising news for individuals struggling with the chronic skin condition lichen planus. Aclaris Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to their investigational drug, modzatinib (ATI-2138), for the treatment of moderate to severe cases of this condition.
What is Fast Track Designation?
The FDA’s Fast Track program is specifically designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address unmet medical needs. Receiving this designation signifies that the regulatory pathway for modzatinib may be streamlined, potentially bringing this therapy to patients who need it sooner.
Understanding Modzatinib (ATI-2138)
Modzatinib is an investigational oral small molecule inhibitor. By targeting specific pathways associated with the inflammation of lichen planus, researchers hope to provide a more effective treatment option for those whose symptoms remain poorly managed by current standards of care.
- Target Condition: Moderate to severe lichen planus.
- Drug Class: Investigational oral small molecule inhibitor.
- Significance: Aims to address a significant unmet medical need in dermatology.
While this is an encouraging milestone, the drug remains under clinical investigation. Patients are encouraged to consult with their dermatologists regarding current treatment options and to stay informed as more data emerges from the clinical trial process.
Source: Read More